Loading company…
VASTHERA develops synthetic therapeutics for vascular and other arterial diseases.
Founded in 2018 and based in Seoul, South Korea, VASTHERA develops therapeutics targeting vascular hyperplasia and arterial diseases, including pulmonary arterial hypertension, restenosis, angina, and heart failure. Its platform focuses on peroxide-based redox signaling. In November 2020, it raised KRW 18 billion in Series B funding from ID Ventures, Medytox Venture Investment, SJ Investment Partners, Daesung Private Equity, Holistic Growth Initiative, Medici Investment, and UTC Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in